Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) had its price objective raised by stock analysts at Barclays from $4.00 to $5.00 in a research report issued on Friday, FlyOnTheWall reports. Barclays‘s price objective indicates a potential upside of 21.65% from the stock’s current price. A number of other brokerages have also weighed in on AMRX. […]